Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s40620-024-02145-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Octreotide-LAR in ADPKD patients with very low kidney function: a single-center real-life experience.
J Nephrol
December 2024
Chair of Nephrology, Department of Public Health, Federico II University, Naples, Italy.
Effects of Octreotide-Long-Acting Release Added-on Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease: Pilot, Randomized, Placebo-Controlled, Cross-Over Trial.
Clin J Am Soc Nephrol
February 2023
Departments of Renal Medicine and Biomedical Engineering, Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò," Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.
Background: Tolvaptan and octreotide-long-acting release (LAR) have renoprotective effects in autosomal dominant polycystic kidney disease (ADPKD) that are partially mediated by amelioration of compensatory glomerular hyperfiltration. We compared the effects of tolvaptan and octreotide-LAR combination therapy versus those of tolvaptan monotherapy in patients with ADPKD.
Methods: This pilot, randomized, placebo-controlled, cross-over trial primarily compared the effects of 1- and 4-week treatments with octreotide-LAR (two 20-mg i.
Article Synopsis
- * Until recently, ADPKD was thought to be untreatable, but scientists have found new ways to help manage the disease with medicines like somatostatin and tolvaptan.
- * Somatostatin is only available in Italy, while tolvaptan is approved worldwide but can be hard for some patients to tolerate.
Therapeutic advances in ADPKD: the future awaits.
J Nephrol
March 2022
Chair of Nephrology "Federico II", Department of Public Health, University of Naples, Via Sergio Pansini, 5, 80131, Naples, Italy.
Article Synopsis
- Autosomal dominant polycystic kidney disease (ADPKD) is a genetic condition that can lead to serious kidney problems, affecting about 1 in 1,000 to 1 in 2,500 people.
- It is mainly caused by changes in two genes called PKD1 and PKD2, which are important for how kidney cells grow and survive.
- New treatments, like tolvaptan and octreotide-LAR, are being tested, and researchers are exploring many other potential drugs to improve the care of people with ADPKD in the future.
[ADPKD treatment: Tolvaptan and Octreotide].
G Ital Nefrol
December 2019
UOC Nefrologia, Dialisi e Litotrissia, Ospedale Sandro Pertini Roma.
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most frequent monogenic hereditary disease as well as the most studied inherited kidney disease. Two drugs have recently been authorized that can slow down the progression of the disease: Tolvaptan (vasopressin receptor antagonist) and Octreotide-LAR (long-acting somatostatin analogue); they both are able to reduce the activity of cyclic adenosine monophosphate (cAMP) and therefore have anti-proliferative and anti-secretory effects. This review analyzes the main trials published to date demonstrating the effects on disease progression in patients with ADPKD and illustrates the indications for identifying subjects eligible for therapy.
View Article and Find Full Text PDF